A narrative review on vaccination rate and factors associated with the willingness to receive pneumococcal vaccine in Chinese adult population. Issue 6 (30th November 2022)

• Record Type: Journal Article
• Authors: Yunhua, Bai; Peng, Bai; Shuping, Li; Zheng, Zhang
• Is Part Of: Human vaccines & immunotherapeutics. Volume 18:Issue 6(2022)
• Publication Date: 2022-11-30
• Subjects: 23-valent pneumococcal polysaccharide vaccine -- PPSV-23 -- pneumonia -- pneumococcal vaccine -- China -- elderly population -- willingness; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2022.2139123
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: The 23-valent pneumococcal polysaccharide vaccine (PPSV-23) is the only approved vaccine for pneumococcal diseases in elderly Chinese population. Though regional studies explored the PPSV-23 vaccination coverage rates and influencing factors in China, a large-scale, nation-wide epidemiological surveillance studies to understand the different factors impeding pneumococcal vaccination rate are required. Hence, this review summarized PPSV-23 coverage rate, analyzed and identified vaccination influencing factors among elderly population across China by exploring articles published in CNKI, Wanfang and PubMed databases. Pneumococcal vaccination coverage rate was found to be low at around 1.23%~42.10% in China. Co-morbidities, knowledge, attitude, perception toward pneumonia and PPSV-23, education level, socio-economic disparities, health education and local policies were some of the factors associated with vaccination willingness among elderly Chinese population. Interventions or policies like government funding, subsidies, inclusion of PPSV-23 in medical insurance, or systematic encouragement from HCPs as key strategies should be implemented to encourage vaccination.